Rh‐endostatin has been recommended as a treatment option for locally advanced and advanced NSCLC and rh‐endostatin combined with chemotherapy for the first‐line treatment of advanced‐stage NSCLC patients without targetable genetic aberrations in Chinese NSCLC treatment guidelines.9, 10. The gene discussed is COL18A1; the disease is non-small cell lung carcinoma.